A first-in-class, first-in-human phase I study of enadenotucirev, an oncolytic Ad11/Ad3 chimeric group B adenovirus, administered intravenously in patients with metastatic epithelial tumors.-Reference-Cited by-同舟云学术

A first-in-class, first-in-human phase I study of enadenotucirev, an oncolytic Ad11/Ad3 chimeric group B adenovirus, administered intravenously in patients with metastatic epithelial tumors.

Published:2014-05-20 Issue:15_suppl Volume:32 Page:3103-3103
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

Calvo Emiliano¹,Gil-Martin Marta²,Machiels Jean-Pascal H.³,Rottey Sylvie⁴,Cubillo Antonio⁵,Salazar Ramon²,Mardjuadi Feby Ingriani⁶,Geboes Karen Paula⁷,Ellis Christopher⁸,Beadle John William⁸,Blanc Christine⁸

Affiliation:

1. START Madrid, Madrid, Spain

2. Early Clinical Research Unit, Institut Català d'Oncologia, L´Hospitalet-Barcelona, Spain

3. Cliniques Universitaires Saint Luc, Université Catholique de Louvain, Brussels, Belgium

4. Ghent University Hospital, Ghent, Belgium

5. START Madrid, Centro Integral Oncológico Clara Campal, Hospital Universitario San Chinarro, Madrid, Spain

6. Cliniques Universitaires Saint Luc, Université Catholique de Louvain, Bruxelles, Belgium

7. Ghent University Hospital, Department of Gastroenterology, Ghent, Belgium

8. PsiOxus Therapeutics Limited, Abingdon, United Kingdom

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Link

http://ascopubs.org/doi/pdfdirect/10.1200/jco.2014.32.15_suppl.3103

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Current status and future perspectives of immunotherapy in bladder cancer treatment;Science China Life Sciences;2020-08-26

2. Immune checkpoint inhibitors for metastatic bladder cancer;Cancer Treatment Reviews;2018-03

3. Toxicity profiles of immunotherapy;Pharmacology & Therapeutics;2018-01

4. Phase 1 study of intravenous administration of the chimeric adenovirus enadenotucirev in patients undergoing primary tumor resection;Journal for ImmunoTherapy of Cancer;2017-09-19

5. Development of a versatile oncolytic virus platform for local intra-tumoural expression of therapeutic transgenes;PLOS ONE;2017-05-18